CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will present at the following virtual healthcare conferences in January:
40th Annual J.P. Morgan Healthcare Conference
HC Wainwright BioConnect Conference
A live webcast of the J.P. Morgan presentation will be available via the Events section of the Company’s investor relations website at https://investors.cullinanoncology.com/news-events/events. Registration and other information about the HC Wainwright Conference can be found at https://hcwevents.com/bioconnect.
About Cullinan Oncology
Cullinan Oncology is a biopharmaceutical company that is developing a diversified pipeline of targeted therapeutic candidates across multiple modalities in order to bring important medicines to cancer patients. The Company’s strategy is to source innovation through both internal discovery efforts and external collaborations, focusing on advanced stage assets with novel technology platforms and differentiated mechanisms. Learn more about Cullinan at www.cullinanoncology.com.
Contacts:
Investor Relations
Lee Roth / Dr. Grace Kim
+1 212.213.0006
Lroth@burnsmc.com / gkim@burnsmc.com
Jeffrey Trigilio
+1 617.410.4650
jtrigilio@cullinanoncology.com
Media
Ariane Lovell
+1 917.565.2204
ariane.lovell@finnpartners.com
The round is led by Danish VC Dreamcraft, together with biotech investor Lundbeckfonden BioCapital and…
BCC Research Identifies Key Sectors with Substantial Growth Potential, Forecasting Significant Market Expansion Through 2029.…
PALO ALTO, CA / ACCESSWIRE / July 3, 2024 / Bioz, Inc., a pioneering AI…
STOCKHOLM, SWEDEN / ACCESSWIRE / July 3, 2024 / iZafe Group (STO:IZAFE-B.ST) iZafe Group AB…
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza…
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation…